Solid lipid nanoparticles
|
100–1000 nm |
Low toxicity, highly effective drug targeting, controlled-release drugs, high drug loads (especially lipophilic drugs), prevents degradation and has versatility |
[112,113,114] |
Lipidosome
|
50–200 nm |
Biocompatible, biodegradable, non-toxic and non-immunogenic |
[115] |
Dendritic polymer |
1.5–14.5 nm |
Spherical homogeneous structure, high biocompatibility, lipophilic, variable composition |
[116] |
Nanocapsule |
10–1000 nm |
Improves efficacy and bioavailability, prevents drug degradation, and provides controlled-release delivery |
[117] |
Polymeric micelle |
10–100 nm |
Improves bioavailability, alters drug release curves, and improves patient compliance |
[118] |
Mesoporous silica material |
2–50 nm |
Good biocompatibility, large specific surface area, large porosity, high drug carrying capacity, good thermal and chemical stability, can carry hydrophilic and lipophilic drugs |
[119,120,121] |
Carbon nano tube |
0.4–2 nm |
Water solubility, biocompatibility, low toxicity, high drug load, intrinsic stability, high specific surface area |
[122,123,124] |
2–100 nm |
Nano-emulsion |
Submicron order |
High stability, high load capacity, improved solubility and bioavailability |
[125] |
Nanocrystal |
1–1000 nm |
Stabilized by surfactants or stabilizers, no need for carrier materials, drug nanocrystals can enhance the adhesion to biofilms, increases the saturation solubility of drugs, large specific surface area, high bioavailability, high stability, high drug loading capacity, stable dissolution, sustained release drugs and safety |
[126,127,128] |